The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1571
May 6, 2019
View Complete Issue         Table of Contents 2019 
Brexanolone (Zulresso) for Postpartum Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brexanolone (Zulresso) for Postpartum Depression
May 6, 2019 (Issue: 1571)
The FDA has approved the GABAA receptor modulator brexanolone (Zulresso – Sage Therapeutics) for IV treatment of postpartum depression (PPD). Brexanolone is the first drug to be approved by the FDA for this indication.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brexanolone (Zulresso) for Postpartum Depression
Article code: 1571b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.